Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics (Q34047193)

30 July 2017

1 reference

title

Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics (English)

1 reference

30 July 2017

Cohen LH

1

1 reference

30 July 2017

Pieterman E

2

1 reference

30 July 2017

van Leeuwen RE

3

1 reference

30 July 2017

Overhand M

4

1 reference

30 July 2017

Burm BE

5

1 reference

30 July 2017

van der Marel GA

6

1 reference

30 July 2017

van Boom JH

7

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

30 July 2017

published in

Biochemical Pharmacology

1 reference

30 July 2017

volume

60

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

1061-1068

1 reference

Protein isoprenylation and methylation at carboxyl-terminal cysteine residues

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Isoprenylated proteins in cultured cells: subcellular distribution and changes related to altered morphology and growth arrest induced by mevalonate deprivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Ras farnesyltransferase: a new therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Inhibition of Ras prenylation: a novel approach to cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Design and synthesis of a protein:Farnesyltransferase inhibitor based on sugar amino acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

3 Prodrug Design for Phosphates and Phosphonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein:farnesyltransferase to different extents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Inhibition of human smooth muscle cell proliferation in culture by farnesyl pyrophosphate analogues, inhibitors of in vitro protein: farnesyl transferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Geranylgeranylpyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

An Essential Role for Rho, Rac, and Cdc42 GTPases in Cell Cycle Progression Through G 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Ras C-terminal processing enzymes--new drug targets?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

The influence of angiogenesis research on management of patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Osteoclasts are required for bone tumors to grow and destroy bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Stimulation of bone formation in vitro and in rodents by statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Statins: lower lipids and better bones?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Prenylation inhibitors in renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

Posttranslational modification of proteins by isoprenoids in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900386-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-2952(00)00386-5

1 reference

30 July 2017

1 reference